Protocol: Forced Degradation (Stress Testing) Study

This is a ready-to-use forced degradation (stress testing) protocol. It generates the evidence that an analytical method is stability-indicating, meaning it resolves the active from every degradation product formed under stress. Replace every <<FILL: ...>> placeholder with your own specifics, set your document numbers and dates, and route it through your normal protocol review and approval before execution. A worked filled specimen follows the blank template. Confirm each cited regulation and chapter against the current source before you rely on it. This content is general educational reference, not regulatory or professional advice; adapt it to your product, your method, and your quality system.

Approval page

1. Objective

To demonstrate that <<FILL: method ID>> is stability-indicating for <<FILL: product>> by subjecting the drug substance and drug product to defined stress conditions, confirming the method resolves the active from all degradation products formed, and confirming the analyte peak is spectrally pure. The study supports the specificity element of method validation under ICH Q2(R2) and the stability-indicating claim used in the stability program under ICH Q1A.

2. Scope

This protocol covers acid, base, oxidative, thermal, humidity, and photolytic stress of <<FILL: drug substance>> and <<FILL: drug product>>, evaluation of resolution to the nearest degradant, peak purity of the analyte, and mass balance. It does not cover full method validation, which is executed under <<FILL: method validation protocol ID>>, nor the routine stability study itself.

3. Definitions

• Forced degradation (stress testing): deliberate degradation of the material under conditions more severe than accelerated stability, to generate likely degradation products and challenge the method’s ability to separate them.
• Stability-indicating method: a validated procedure that accurately measures the active without interference from degradation products, process impurities, or excipients.
• Peak purity: the assessment, usually by photodiode-array (PDA) spectral comparison or mass spectrometry, that a chromatographic peak represents a single component with no hidden co-elution.
• Mass balance: the reconciliation of the assay value plus total measured degradants back toward the initial (unstressed) content, accounting for response-factor differences.

4. Responsibilities

5. Prerequisites (confirm before starting)

1. Method <<FILL: method ID>> is at a controlled, frozen revision.
2. The HPLC/UPLC system and PDA (or MS) detector are within qualification and calibration for the whole execution period. See analytical-instrument-qualification.
3. Reference standard lot <<FILL: lot>>, assigned potency <<FILL: %>>, certificate on file, sufficient quantity for the study plus repeats.
4. System suitability criteria for the method are established and met (see method-validation-execution).
5. Acceptance criteria in section 7 are approved before any sample is stressed.

6. Stress conditions and target degradation

Target roughly 5 to 20 percent loss of the active for each condition that degrades it. Too little proves nothing; total destruction generates secondary degradants that never form under real storage. “No degradation under this condition” is a valid, documented result, not a gap. Adjust the concentrations, temperatures, and durations to the molecule; the values below are typical starting points.

Prepare a reagent blank for each solution stress so any reagent peak is identified and excluded.

7. Acceptance criteria

8. Test cases (record per condition)

For each condition, record the actual conditions applied, percent degradation, resolution to the nearest degradant, peak-purity result, mass balance, pass/fail, tester, and date.

9. Deviation handling

Any departure from the protocol (a condition that over-degrades, an instrument fault, an out-of-window calibration) is recorded as a protocol deviation with an impact assessment, and the affected sample is re-stressed or re-injected as appropriate. A condition that over-degrades on the first attempt is repeated at a shorter time or lower concentration to land in the target window; both attempts are documented. See validation-test-failure-management.

10. Summary and conclusion

Summarize which conditions degraded the active and to what extent, the resolution and peak-purity results, the mass-balance outcome, and any conditions that produced no degradation. State the overall conclusion: the method is, or is not, demonstrated stability-indicating for the product across the stress conditions studied. Where a condition revealed a poorly resolved degradant, describe the method adjustment made and whether re-execution was needed.

11. Attachments

• Chromatograms for each stressed sample, the unstressed control, blanks, and placebo.
• Peak-purity reports (PDA or MS) for each analyte peak.
• Reference standard certificate and preparation worksheets.
• Raw data and sequence with integration parameters.

12. Revision history

13. References

21 CFR 211.165(e) (establishment of method accuracy, sensitivity, specificity, reproducibility) and 211.194(a)(2). ICH Q2(R2), Validation of Analytical Procedures (specificity). ICH Q1A(R2), Stability Testing, and ICH Q1B, Photostability Testing (stress-testing expectation). ICH Q3A(R2)/Q3B(R2), Impurities in New Drug Substances/Products (reporting and identification thresholds). USP General Chapter <1225>, Validation of Compendial Procedures.

Confirm the current version and clause numbers of each reference before issue.

Filled specimen

The following shows the test-case table completed for an illustrative small-molecule tablet assay method. Company, method, and numbers are illustrative; replace them with your own.

Method: TM-1042 v3, reversed-phase HPLC assay and related substances. Reference standard: lot RS-2208, potency 99.4 percent. Target degradation window: 5 to 20 percent.

Conclusion (specimen): Acid, base, oxidation, and light produced degradation inside the target window; thermal and humidity produced little to none, documented as such. Every stressed analyte peak was spectrally pure and resolved from its nearest degradant at not less than 2.4. Mass balance reconciled within 98.3 to 100.2 percent. The base condition ran closest to the resolution limit at 2.4, so the method’s system suitability resolution criterion of not less than 2.0 is confirmed as the routine guardrail. TM-1042 v3 is demonstrated stability-indicating for the product across the conditions studied.

Common inspection findings this protocol prevents

• A “stability-indicating” claim with no forced degradation data behind it.
• Over-stressing until the active is gone, generating artificial degradants and nuisance resolution work.
• Relying on resolution alone and skipping peak purity, so a perfectly co-eluting impurity goes undetected.
• No placebo or blank, so an excipient or reagent peak is mistaken for a degradant (or masks one).
• Mass balance never reconciled and the gap never explained.
• Photolytic stress run without a dark control, so thermal and photolytic effects cannot be separated.

How to adapt this protocol

1. Set your document number, method ID, product, and reference standard details on the approval page.
2. Tune each stress condition in section 6 to your molecule; a stable compound may need harsher acid/base or longer times to reach the target window, a labile one much milder.
3. Set the resolution and mass-balance limits in section 7 from your method capability and product knowledge.
4. If you use MS rather than PDA for peak purity, state the acceptance basis (for example, no additional mass within the peak).
5. Confirm every regulation and USP chapter in section 13 against the current published version before issue.